FCF Payout Ratio: 18.48%
Is the FCF payout ratio high or low?
The FCF payout ratio of 18.48% is in line with its 5-year average of 20.08%, around the middle of its 5-year range (16.12%–23.39%).
12.67% below its 12-month average of 21.16%.
TECH FCF Payout Ratio
Rolling trailing-12-month FCF payout ratio sampled each quarter; raw quarterly payout is intentionally not charted.
TECH Average FCF Payout Ratio Chart
TECH Current vs Average FCF Payout Ratio Chart
TECH FCF Payout Ratio Metrics
FCF PAYOUT RATIO
18.48%
FCF PAYOUT RATIO AVG TTM
21.16%
FCF PAYOUT RATIO AVG 3Y
21.41%
FCF PAYOUT RATIO AVG 5Y
20.08%
FCF PAYOUT RATIO AVG 10Y
26.39%
FCF PAYOUT RATIO AVG 15Y
29.95%
FCF PAYOUT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-12.67%
CURRENT VS 3Y AVG
-13.69%
CURRENT VS 5Y AVG
-7.96%
CURRENT VS 10Y AVG
-29.99%
CURRENT VS 15Y AVG
-38.30%
CURRENT VS 20Y AVG
N/A
Payout Ratio Comparison
FCF Payout Ratio TTM
18.5%
Earnings Payout Ratio
68.1%
Dividend Yield
0.45%
FCF Yield
2.42%
Annual FCF Payout Ratio History
| Year | Free Cash Flow | Dividends Paid | FCF Payout Ratio |
|---|---|---|---|
| 2025 | $256.55M | $50.39M | 19.6% |
| 2024 | $236.10M | $50.42M | 21.4% |
| 2023 | $216.15M | $50.28M | 23.3% |
| 2022 | $280.36M | $50.19M | 17.9% |
| 2021 | $307.86M | $49.62M | 16.1% |
| 2020 | $153.47M | $48.90M | 31.9% |
| 2019 | $156.21M | $48.36M | 31.0% |
| 2018 | $149.43M | $47.97M | 32.1% |
| 2017 | $128.27M | $47.33M | 36.9% |
| 2016 | $126.97M | $47.61M | 37.5% |
| 2015 | $119.45M | $47.11M | 39.4% |
| 2014 | $122.94M | $45.39M | 36.9% |
| 2013 | $101.11M | $43.46M | 43.0% |
| 2012 | $120.73M | $41.02M | 34.0% |
| 2011 | $123.56M | $39.69M | 32.1% |
| 2010 | $106.62M | $38.39M | 36.0% |
| 2009 | $104.77M | $28.19M | 26.9% |
| 2008 | $98.95M | $0 | 0.0% |
| 2007 | $82.43M | $0 | 0.0% |
| 2006 | $80.99M | $0 | 0.0% |
| 2005 | $63.02M | $0 | 0.0% |
| 2004 | $61.84M | $0 | 0.0% |
| 2003 | $38.90M | $0 | 0.0% |
| 2002 | $5.39M | $0 | 0.0% |
| 2001 | $39.56M | $0 | 0.0% |
| 2000 | $8.37M | $0 | 0.0% |
| 1999 | ($2.20M) | $0 | N/A (Loss) |
| 1998 | $17.30M | $0 | 0.0% |
| 1997 | $8.30M | $0 | 0.0% |
| 1996 | $3.40M | $0 | 0.0% |
Formula: FCF Payout Ratio TTM = trailing 4Q dividends paid / trailing 4Q free cash flow × 100
FCF payout and earnings payout:
- FCF represents operating cash flow after capital expenditures
- FCF payout compares dividends paid with free cash flow
- FCF payout above 100% means dividends paid exceeded free cash flow for the period
- Earnings payout compares dividends paid with net income
Reading the series: Use the chart and table to compare dividend payments with cash generation over time.
FCF Payout Ratio Formula & Definition
FCF Payout Ratio measures trailing dividends paid as a percentage of trailing free cash flow. Unlike earnings-based payout, it compares dividends with cash generated after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
FCF Payout Ratio FAQ
- What is the FCF payout ratio for Bio-Techne Corporation (TECH)?
- The FCF payout ratio for TECH stock is 18.48%.
- Is Bio-Techne Corporation's FCF payout ratio high or low?
- The FCF payout ratio of 18.48% is in line with its 5-year average of 20.08%, around the middle of its 5-year range (16.12%–23.39%).
- What is the TTM average FCF payout ratio for Bio-Techne Corporation (TECH)?
- The TTM average FCF payout ratio for TECH stock is 21.16%.
- What is the 3Y average FCF payout ratio for Bio-Techne Corporation (TECH)?
- The 3Y average FCF payout ratio for TECH stock is 21.41%.
- What is the 5Y average FCF payout ratio for Bio-Techne Corporation (TECH)?
- The 5Y average FCF payout ratio for TECH stock is 20.08%.
- What is the 10Y average FCF payout ratio for Bio-Techne Corporation (TECH)?
- The 10Y average FCF payout ratio for TECH stock is 26.39%.
- What is the 15Y average FCF payout ratio for Bio-Techne Corporation (TECH)?
- The 15Y average FCF payout ratio for TECH stock is 29.95%.
TECH FCF Payout Ratio History
| DATE | FCF PAYOUT RATIO |
|---|---|
| 2026-03-31 | 18.48% |
| 2025-12-31 | 22.37% |
| 2025-09-30 | 22.38% |
| 2025-06-30 | 19.64% |
| 2025-03-31 | 22.94% |
| 2024-12-31 | 19.91% |
| 2024-09-30 | 20.59% |
| 2024-06-30 | 21.35% |
| 2024-03-31 | 20.06% |
| 2023-12-31 | 22.36% |
| 2023-09-30 | 23.39% |
| 2023-06-30 | 23.26% |
| 2023-03-31 | 21.58% |
| 2022-12-31 | 19.93% |
| 2022-09-30 | 17.66% |
| 2022-06-30 | 17.90% |
| 2022-03-31 | 16.59% |
| 2021-12-31 | 16.21% |
| 2021-09-30 | 16.87% |
| 2021-06-30 | 16.12% |
| 2021-03-31 | 22.01% |
| 2020-12-31 | 24.57% |
| 2020-09-30 | 27.49% |
| 2020-06-30 | 31.86% |
| 2020-03-31 | 28.64% |
| 2019-12-31 | 29.47% |
| 2019-09-30 | 32.11% |
| 2019-06-30 | 30.96% |
| 2019-03-31 | 28.23% |
| 2018-12-31 | 31.21% |
| 2018-09-30 | 33.10% |
| 2018-06-30 | 32.10% |
| 2018-03-31 | 35.05% |
| 2017-12-31 | 34.31% |
| 2017-09-30 | 32.86% |
| 2017-06-30 | 36.90% |
| 2017-03-31 | 40.92% |
| 2016-12-31 | 36.68% |
| 2016-09-30 | 38.16% |
| 2016-06-30 | 37.49% |
| 2016-03-31 | 38.42% |
| 2015-12-31 | 41.21% |
| 2015-09-30 | 41.56% |
| 2015-06-30 | 39.43% |
| 2015-03-31 | 37.33% |
| 2014-12-31 | 35.60% |
| 2014-09-30 | 36.66% |
| 2014-06-30 | 36.92% |
| 2014-03-31 | 40.24% |
| 2013-12-31 | 41.38% |
| 2013-09-30 | 42.86% |
| 2013-06-30 | 42.99% |
| 2013-03-31 | 37.89% |
| 2012-12-31 | 35.30% |
| 2012-09-30 | 36.19% |
| 2012-06-30 | 33.98% |
| 2012-03-31 | 34.57% |
| 2011-12-31 | 34.63% |
| 2011-09-30 | 31.50% |
| 2011-06-30 | 32.12% |
| 2011-03-31 | 32.57% |
| 2010-12-31 | 35.20% |
| 2010-09-30 | 35.58% |
| 2010-06-30 | 36.01% |
| 2010-03-31 | 36.94% |
| 2009-12-31 | 34.99% |
| 2009-09-30 | 26.36% |
| 2009-06-30 | 17.84% |
| 2009-03-31 | 9.23% |
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kim Kelderman